Ipatasertib Market Report 2026

Ipatasertib Market Overview

• Ipatasertib market size has reached to $0.86 billion in 2025 • Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 13.1% • Growth Driver: Increasing Prevalence Of Cancer Fueling The Growth Of The Market Due To Rising Cancer Incidences And Need For Targeted Therapies • North America was the largest region in 2025.

What Is Covered Under Ipatasertib Market?

Ipatasertib is an oral, small-molecule inhibitor that selectively targets protein kinase B (AKT), a key protein in the phosphoinositide 3-kinase (PI3K) or protein kinase B (AKT) signaling pathway that is often overactive in cancer cells. It works by inhibiting protein kinase B (AKT) and disrupting cancer cell growth, survival, and proliferation, helping to slow cancer progression and enhance the effectiveness of other therapies. The main indications of ipatasertib are prostate cancer, breast cancer, and others. Prostate cancer is a disease that develops in the prostate, a small gland in men responsible for producing seminal fluid. It is available in various dosage forms, including tablets, capsules, and others, and is administered through oral or intravenous routes. Ipatasertib is distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Ipatasertib Market Growth Forecast?

The ipatasertib market size is expected to see rapid growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted cancer drugs, rising demand for personalized cancer therapies, expansion of combination therapy strategies, growing investments in oncology R&D, increasing focus on resistant cancer treatment options. Major trends in the forecast period include increasing focus on akt pathway inhibition therapies, rising use of combination cancer treatment regimens, growing emphasis on biomarker-driven oncology drugs, expansion of targeted small-molecule pipelines, enhanced clinical evaluation of precision oncology agents.

Global Ipatasertib Market Segmentation

1) By Indication: Prostate Cancer, Breast Cancer, Other Cancers 2) By Dosage Form: Tablets, Capsules, Other Dosages 3) By Route Of Administration: Oral, Intravenous 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Prostate Cancer: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Prostate Cancer 2) By Breast Cancer: Triple-Negative Breast Cancer (TNBC), Hormone Receptor-Positive Or Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer 3) By Other Cancers: Ovarian Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer, Lung Cancer

What Are The Drivers Of The Ipatasertib Market?

The increasing prevalence of cancer is expected to propel the growth of the ipatasertib market going forward. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to lifestyle choices such as poor diet, smoking, physical inactivity, and excessive alcohol consumption. Ipatasertib enhances cancer treatment strategies by targeting the PI3K/AKT signaling pathway, making it effective in slowing tumor growth and proliferation. It reduces cancer cell survival and resistance to therapy, improving treatment outcomes and patient prognosis. For instance, in April 2024, according to the American Cancer Society (ACS) and the International Agency for Research on Cancer (IARC), there were 20 million new cancer cases in 2022, up from previous estimates, with projections to reach 35 million by 2050, representing a 77% increase. Therefore, the increasing prevalence of cancer is driving the growth of the ipatasertib industry. The rising preference for personalized medicine is expected to propel the growth of the ipatasertib market going forward. Personalized medicine refers to a medical approach that tailors treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The increasing adoption of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Ipatasertib enhances personalized medicine by targeting the PI3K/AKT signaling pathway, making cancer treatment more tailored to individual patient tumor profiles. It improves therapeutic effectiveness by addressing specific genetic and molecular characteristics, reducing treatment resistance, and optimizing patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the rising preference for personalized medicine is driving the growth of the ipatasertib industry. The rising healthcare expenditure is expected to propel the growth of the ipatasertib market going forward. Healthcare expenditure refers to the total amount of money spent on medical services, treatments, facilities, research, and public health initiatives to maintain or improve health outcomes. The increasing demand for healthcare expenditure is due to the rising prevalence of chronic diseases, which require long-term and costly treatments. Rising healthcare expenditure enhances Ipatasertib development by providing increased funding and resources for research and clinical trials, making it easier to advance innovative cancer therapies. It accelerates drug development timelines and supports broader access to targeted treatments, improving patient outcomes and treatment efficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure saw a 5.6% increase in nominal terms in 2023, an increase of 0.9% growth compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the ipatasertib industry.

Key Players In The Global Ipatasertib Market

Major companies operating in the ipatasertib market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation

Regional Insights

North America was the largest region in the ipatasertib market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ipatasertib Market?

The ipatasertib market consists of sales of capivasertib (AZD5363), perifosine, afuresertib (GSK2110183), MK-2206, and taselisib (GDC-0032). Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ipatasertib Market Report 2026?

The ipatasertib market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ipatasertib industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.